SCHEMBL279600

SCHEMBL279600

Cc1ccc(C(=O)NN2CCOCC2)s1

nearest known ligand 0.69

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.69
CYP2D6 P10635 1/20 0.57
KMT2A Q03164 4/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
LMNA P02545 1/20 0.50
MAPK1 P28482 1/20 0.50
ALDH1A1 P00352 3/20 0.49
MEN1 O00255 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.48
KDM4E B2RXH2 1/20 0.46
ADORA2A P29274 1/20 0.45
POLB P06746 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
HPGD P15428 1/20 0.45
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL279935 0.84 KMT2A (0.54) HTTKMT2ALMNAMAPK1ALDH1A1
SCHEMBL279590 0.83 KMT2A (0.71) HTTCYP2D6KMT2ASMN1; SMN2LMNA
SCHEMBL12313815 0.82 HTT (0.66) HTTCYP2D6KMT2ASMN1; SMN2LMNA
SCHEMBL276182 0.82 HTT (0.66) HTTCYP2D6KMT2ASMN1; SMN2LMNA
SCHEMBL276922 0.82 HTT (0.69) HTTCYP2D6KMT2ASMN1; SMN2LMNA
SCHEMBL12265883 0.81 HTT (0.64) HTTCYP2D6KMT2ASMN1; SMN2LMNA
SCHEMBL14395480 0.81 HTT (0.68) HTTCYP2D6KMT2ASMN1; SMN2LMNA
SCHEMBL4160220 0.76 HPGD (0.77) HTTSMN1; SMN2ALDH1A1L3MBTL1KDM4E
SCHEMBL279580 0.76 KMT2A (0.62) KMT2ALMNAALDH1A1MEN1L3MBTL1
SCHEMBL15297484 0.75 CYP2D6 (0.52) HTTCYP2D6KMT2ASMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL HTT 1630/4885CYP2D6 2749/4885KMT2A 3398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.